BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (Gain, or the Company), a clinical-stage biotechnology company leading the discovery and development of...
BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (Gain, or the Company), a clinical-stage biotechnology company leading the discovery and development of...
BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (Gain, or the Company), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics Reports Financial Results for Year End 2023
Gain Therapeutics to Present at Public Ventures Discovery Day
Gain Therapeutics Presents Data at the AD/PD 2024 Conference
BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (œGain, or the œCompany), a clinical-stage biotechnology company leading the discovery and development of...
BETHESDA, Md., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of...
BETHESDA, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of...
Gain Therapeutics’ phase 1 drug for Parkinson’s disease associated with a common gene mutation appears to restore motor function in mice, even after a delay between symptom onset and treatment, new data from the company have shown.